Genovate Biotechnology Co., Ltd. (4130.TWO)
- Previous Close
20.95 - Open
21.30 - Bid 20.95 x --
- Ask 21.00 x --
- Day's Range
20.95 - 21.30 - 52 Week Range
18.50 - 26.40 - Volume
49,078 - Avg. Volume
159,754 - Market Cap (intraday)
2.336B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
91.09 - EPS (TTM)
0.23 - Earnings Date --
- Forward Dividend & Yield 0.15 (0.72%)
- Ex-Dividend Date Aug 21, 2024
- 1y Target Est
--
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. The company was founded in 1982 and is based in Hsinchu City, Taiwan.
www.genovate-bio.comRecent News: 4130.TWO
View MorePerformance Overview: 4130.TWO
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4130.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4130.TWO
View MoreValuation Measures
Market Cap
2.34B
Enterprise Value
1.82B
Trailing P/E
91.09
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.58
Price/Book (mrq)
1.61
Enterprise Value/Revenue
3.56
Enterprise Value/EBITDA
26.18
Financial Highlights
Profitability and Income Statement
Profit Margin
5.03%
Return on Assets (ttm)
0.92%
Return on Equity (ttm)
1.76%
Revenue (ttm)
510.86M
Net Income Avi to Common (ttm)
25.7M
Diluted EPS (ttm)
0.23
Balance Sheet and Cash Flow
Total Cash (mrq)
521.47M
Total Debt/Equity (mrq)
0.18%
Levered Free Cash Flow (ttm)
27.83M